MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 705-708

  Sasaki, Hidefumi ^a   Shitara, Masayuki ^a   Yokota, Keisuke ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Lung cancer; Multidrug resistant protein 3; Mutation; NRF2; Squamous cell carcinoma

Indexed keywords

BETA ACTIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3; TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; NF-E2-RELATED FACTOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SURVIVAL RATE;

EID: 84865185508     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.979     Document Type: Article

References (26)

1. Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA (eds). 4th edition. Lippincott, Williams and Wilkins, Philadelphia, pp673-682, 1993.
2. Sakata R, Fujii Y and Kuwano H: Thoracic and cardiovascular surgery in Japan during 2009. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 59: 636-667, 2011.
3. Postus PE: Chemotherapy for non-small cell lung cancer: the experience of the lung cancer cooperative group of the European Organization for Research and Treatment of Cancer. Chest 113 (Suppl 1): S28-S31, 1998.
4. Kensler TW and Wakabayashi N: Nrf2: friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
5. Moi P, Chank K, Asunis I, et al: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91: 9926-9930, 1994. (Pubitemid 24311921)
6. Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
7. Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol 5: 786-789, 2010.
8. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
9. Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 39: 4743-4747, 2012.
10. Young LC, Campling BG, Voskoglou-Nomikos T, et al: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5: 673-680, 1999. (Pubitemid 29131979)
11. Kool M, van der Linden M, de Haas M, et al: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919, 1999. (Pubitemid 29274984)
12. Lockhart AC, Tirona RG and Kim RB: Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2: 685-698, 2003.
13. Mahaffey CM, Zhang H, Rinna A, et al: Multidrug resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small cell lung carcinoma. Free Radic Biol Med 46: 1650-1657, 2009.
14. Merikallio H, Pääkkö P, Kinnula VL, et al: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 43: 577-584, 2012.
15. Yang H, Wang W, Zhang Y, et al: The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small cell lung carcinomas. Clin Lung Cancer 12: 166-171, 2011.
16. Mahaffey CM, Mahaffey NC, Holland W, et al: Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol 7: 34-39, 2012.
17. Mahaffey CM, Zhang H, Rinna A, et al: Multidrug resistant protein-three gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small cell lung carcinoma. Free Radiac Biol Med 46: 1650-1657, 2009.
18. Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997. (Pubitemid 27373291)
19. Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3: 481-490, 2002. (Pubitemid 34987481)
20. Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37: 433-441, 2004. (Pubitemid 38901076)
21. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
22. Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology 55: 750-754, 2008. (Pubitemid 351741541)
23. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
24. Zhou J, Schmid T, Schnitzer S and Brüne B: Tumor hypoxia and cancer progression. Cancer Lett 237: 10-21, 2006.
25. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
26. Cho JM, Manandhar S, Lee HR, et al: Role of Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 260: 96-108, 2008.